The GSK3B Knockout HT29 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal cell population derived from the HT29 human colorectal adenocarcinoma cell line, with targeted disruption of the GSK3B gene. This knockout model enables loss-of-function analysis of glycogen synthase kinase-3 beta in an intestinal epithelial background. The polyclonal format provides a heterogeneous edited pool, suitable for assessing population-level effects.
HT29 cells were established from a primary colorectal adenocarcinoma of a 44-year-old female patient. As adherent epithelial cells capable of mucin production under differentiation conditions, they serve as a well-characterized model of human intestinal epithelium and are widely employed in colorectal cancer research due to their retention of oncogenic signaling pathways.
GSK3B encodes a constitutively active serine/threonine kinase that functions as a central negative regulator of the Wnt/??-catenin pathway. In unstimulated cells, GSK3B phosphorylates ??-catenin (CTNNB1) within the AXIN1/2-APC-CK1?? destruction complex, marking it for ubiquitination and proteasomal degradation. Wnt ligand binding (e.g., Wnt3a) to Frizzled/LRP5/6 leads to DVL-mediated inhibition of the complex, ??-catenin stabilization, nuclear translocation, and TCF/LEF-dependent transcription of targets such as MYC and AXIN2. Insulin signaling through AKT phosphorylates GSK3B at Ser9, further reducing its activity. GSK3B also regulates glycogen synthase (GYS1), c-Myc, c-Jun, Tau, and Snail, linking it to insulin signaling, cell proliferation, apoptosis, and migration.
In the HT29 colorectal cancer context, GSK3B disruption enables dissection of its contributions to Wnt-driven proliferation, differentiation, and tumorigenic properties. As HT29 cells exhibit aberrant Wnt pathway activation, GSK3B knockout may reveal compensatory regulatory mechanisms or expose vulnerabilities in downstream signaling. This model is valuable for studying cross-talk between Wnt, insulin/PI3K-Akt, and TNF/NF-??B pathways, which are commonly dysregulated in colorectal carcinoma.
Key applications include TOP/FOP Flash luciferase reporter assays for ??-catenin transcriptional activity, RT-qPCR analysis of Wnt target genes (MYC, AXIN2), and Western blotting for total and Ser9-phosphorylated GSK3B and ??-catenin. Functional studies encompass MTS/MTT proliferation assays, Annexin V apoptosis detection, and migration/invasion assays. Co-immunoprecipitation can assess interactions among ??-catenin, AXIN1, and APC. The model is suitable for GSK3B inhibitor screening and target validation in colorectal cancer drug discovery. For further technical inquiries, please contact Ascent Research.
